Leiomyosarcoma of the renal vein: analysis of outcome and prognostic factors in the world case series of 67 patients

Marko Novak, Andraz Perhavec, Katherine E. Maturen, Snezana Pavlovic Djokic, Simona Jereb, Darja Erzen

doi:10.1515/raon-2016-0051

SUPPLEMENTARY TABLE 3. Reported leiomyosarcoma of the renal vein cases.

| Case | Author et al. | Year | Place | Age | Gender | Side | Dissemi. | IVC extension | Neoadjuvant | Operation | Adjuvant | Size | Grade | Margins | Progression | Outcome | FU months |
|------|---------------|------|-------|-----|--------|------|----------|--------------|-------------|------------|----------|-------|-------|--------|-------------|---------|-----------|
| 1    | Lopez Varela  | 1967 | Costa Rica | 40 | F | R | No | No | No | N | No | 8,0 | * | * | M | DOD | 96 |
| 2    | Bhathena et al. (Montgomery et al.) | 1972 | USA | 50 | F | L | No | No | No | N | No | 7,5 | * neg | LR + M | DOD | 40 |
| 3    | Gierson et al. | 1976 | USA | 54 | F | L | No | No | No | T | No | 25,0 | * | * | NED | 78 |
| 4    | Appel et al. | 1977 | USA | 60 | F | L | No | No | No | N | No | 5,0 | * | * | M | DOD | 16 |
| 5    | Stringer BD. | 1977 | USA | 59 | F | L | No | No | No | T | No | 5,0 | * | * | LR + M | DOD | 72 |
| 6    | Radhakrishnan et al. | 1978 | USA | 93 | F | L | No | No | No | N | No | * | * | M | D = NED | 90 |
| 7    | Kaufman et al. | 1981 | USA | 42 | F | R | No | Yes CT + XRT | N | CT | * | 1 neg | * | NED | 48 |
| 8    | Herman et al. | 1981 | USA | 48 | F | L | No | No | No | N | No | 5,0 | 1 | * | M | DOD | 48 |
| 9    | Dufour et al. | 1982 | France | 73 | F | R | No | Yes + WI | No | N | No | * | * | * | LR + M | DOD | 18 |
| 10   | Hisa et al. | 1984 | Japan | 52 | F | L | No | No | No | T | No | * | * | * | NED | 8 |
| 11   | Hisashi et al. | 1984 | Japan | 52 | F | L | No | No | No | N | XRT | 7,0 | * | * | NED | 8 |
| 12   | Farges et al. (Martin B. et al.) | 1986 | France | 54 | F | R | No | Yes | No | N | CT | 11,0 | * neg | LR | AW D | 6 |
| 13   | Martin B. et al. | 1986 | France | 64 | M | L | No | No | No | N | No | 20,0 | * | * | M | AW D | 24 |
| 14   | Phoa et al. | 1988 | Netherlands | 60 | F | R | No | Yes + WI | No | N | No | 6,0 | 1 | * | M | DOD | 48 |
| 15   | Vos et al. | 1988 | Netherlands | 65 | F | R | No | WI | No | N | No | 6,0 | * | * | M | DOD | 45 |
| 16   | Martin J. et al. | 1989 | Spain | 48 | F | L | No | No | No | N | No | 5,0 | * | * | NED | 48 |
| 17   | Farah et al. | 1989 | USA | 40 | M | R | No | No | No | N | No | 7,5 | 2 | * | * | * | * |
| 18   | Higaki et al. | 1989 | Japan | 51 | F | L | No | No | No | N | CT | * | * | * | M | AW D | 14 |
| 19   | Ball et al. | 1990 | UK | 58 | F | L | No | No | No | N | No | 12,0 | * | * | M | DOD | 12 |
| 20   | Ball et al. | 1990 | UK | 53 | M | L | Yes | No | No | N | No | 7,0 | 2 pos | LR + M | DOD | 30 |
| 21   | Pelton et al. (Brandes et al.) | 1990 | USA | 27 | F | L | Yes | No | No | N | ORT | 15,0 | 2 | * | LR + M | DOD | 54 |
| 22   | Grignon et al. | 1991 | USA | 61 | F | R | Yes | No | No | N | CT | 5,0 | 3 | * | LR | DOD | 30 |
| 23   | Hirao et al. | 1991 | Japan | 52 | F | L | No | No | No | N | Immunotherapy | 8,0 | * | * | NED | 6 |
| 24   | Lakhdhiri et al. | 1992 | Morocco | 60 | F | L | No | No | No | N | No | 16,0 | * | * | * | * |
| 25   | Matsunoaga et al. | 1992 | Japan | 65 | F | L | No | No | No | N | No | 6,0 | * | * | * | * |
| 26   | Inoue et al. | 1994 | Japan | 75 | F | L | No | No | No | N | No | 6,7 | 1 | * | NED | 4 |
| 27   | Lipton et al. | 1995 | USA | 64 | F | L | No | Yes | Embolization | N | No | 23,0 | 3 | * | * | NED | * |
| 28   | Alonso Garcia et al. (RTNBL) | 1996 | Spain | 40 | M | L | No | No | No | N | XRT | 18,0 | 3 | * | LR + M | DOD | 22 |
| 29   | Brandes et al. | 1996 | USA | 70 | M | R | No | No | No | N | No | 6,4 | neg | * | NED | 51 |
| 30   | Brandes et al. | 1996 | USA | 71 | M | L | Yes | No | No | N | No | 10,0 | * | * | M | DOD | 25 |
| 31   | Polsky et al. | 1997 | USA | 56 | F | L | No | No | No | N | No | 6,0 | * | * | NED | 12 |
| 32   | Hattori et al. | 1997 | Japan | 39 | F | L | No | No | No | N | No | 7,0 | * | * | M | AW D | 8 |
| Case | Author            | Year | Place  | Age | Gender | Side | Dissemi. | IVC extension | Neoadjuvant | Operation | Adjuvant | Size | Grade | Margins | Progression | Outcome | FU months |
|------|-------------------|------|--------|-----|--------|------|----------|---------------|--------------|------------|----------|--------|------|-------|---------|-------------|---------|-----------|
| 33   | Maglione et al.   | 1999 | Argentina | 55  | F      | L    | No       | No            | No           | N         | No       | 4.0   | 1     | *      | *        | M         | AWD       | 24        |
| 34   | Inoue et al.      | 2000 | Japan   | 44  | F      | R    | No       | No            | No           | N         | No       | 8.0   | *     | *      | *        | NED       | 8         |
| 35   | Soulie et al.     | 2001 | France  | 35  | M      | R    | No       | No            | No           | N         | XRT     | 10.0  | 2     | *      | M        | DOD       | 9         |
| 36   | Hiratuka et al.   | 2001 | Japan   | 54  | F      | L    | No       | No            | No           | N         | No       | 4.0   | 1     | *      | *        | NED       | 22        |
| 37   | Fuji et al.       | 2001 | Japan   | 68  | F      | L    | No       | No            | No           | N         | No       | 4.0   | *     | *      | *        | *         |           |
| 38   | Kaukhi et al.     | 2002 | USA     | 49  | F      | R    | No       | Yes           | No           | N         | No       | 8.5   | 3     | neg    | M        | DOD       | *         |
| 39   | Ozeki et al.      | 2002 | Japan   | 64  | M      | R    | No       | No            | No           | N         | No       | 4.0   | *     | *      | *        | *         |           |
| 40   | Waki et al.       | 2002 | Japan   | 64  | M      | R    | No       | No            | No           | N         | No       | 4.0   | *     | *      | *        | *         |           |
| 41   | Lemos et al.      | 2003 | Brasil  | 47  | M      | L    | No       | No            | No           | N         | No       | 8.5   | 1     | neg    | M        | DOD       | *         |
| 42   | Mugihara et al.   | 2003 | Japan   | 64  | F      | R    | No       | No            | No           | N         | No       | 11.0  | *     | *      | M        | DOD       | 12        |
| 43   | Kołodziej et al.  | 2004 | Poland  | 75  | F      | R    | No       | No            | No           | T         | XRT     | 6.0   | 2     | pos    | LR       | DOD       | 34        |
| 44   | Colon-Rodriguez et al. | 2004 | Spain  | 63  | F      | L    | No       | No            | No           | N         | No       | 15.0  | 2     | neg    | M        | AWD       | 8         |
| 45   | Aguilar et al.    | 2005 | Peru    | 76  | F      | L    | No       | No            | No           | N         | XRT     | 8.0   | 2     | neg    | M        | DOD       | 24        |
| 46   | Nakagawa et al.   | 2005 | Japan   | 40  | F      | L    | No       | No            | No           | N         | No       | 8.5   | 1     | neg    | NED      | *         |           |
| 47   | Marsencal et al.  | 2006 | France  | 63  | M      | L    | No       | Yes           | No           | no        | CT      | *     | *     | *      | NED       | *         |
| 48   | Hamada et al.     | 2006 | Japan   | 50  | F      | L    | No       | No            | No           | N         | No       | 10.0  | *     | *      | *        | *         |           |
| 49   | Maeda et al.      | 2006 | Japan   | 67  | F      | R    | No       | No            | No           | N         | No       | 5.3   | *     | *      | *        | NED       | 24        |
| 50   | Marousti et al.   | 2006 | Maroc   | 54  | F      | R    | No       | No            | No           | N         | XRT     | 15.0  | *     | *      | *        | NED       | 9         |
| 51   | Nese et al.       | 2008 | Turkey  | 62  | F      | L    | No       | No            | No           | N         | No       | 8.5   | 1     | neg    | NED      | 24        |
| 52   | Ikegami et al.    | 2009 | Japan   | 40  | F      | L    | No       | No            | No           | N         | No       | 8.0   | *     | *      | *        | NED       | 66        |
| 53   | Gonzalez-Rodriguez et al. | 2009 | Spain  | 59  | F      | L    | No       | No            | No           | C         | XRT     | 13.0  | 3     | neg    | *        | NED       | 17        |
| 54   | Kato et al.       | 2009 | Japan   | 52  | M      | L    | No       | No            | No           | LAP N     | 5.3   | *     | *      | *        | NED       | 24        |
| 55   | Frydenberg et al. | 2010 | Australia | 66  | F      | L    | No       | No            | No           | N         | No       | 3.5   | 3     | neg    | LR + M   | NED       | 65        |
| 56   | Hovliene et al.   | 2010 | France  | 68  | F      | L    | No       | Yes           | No           | N         | No       | 3.0   | 3     | neg    | *        | NED       | 24        |
| 57   | Imao et al.       | 2011 | Japan   | 43  | F      | L    | No       | No            | No           | [LAP] N   | 5.5   | *     | *      | *        | NED       | 24        |
| 58   | Douma et al.      | 2012 | Greece  | 43  | F      | L    | No       | No            | No           | N         | No       | 12.0  | 3     | *      | NED      | 24        |
| 59   | Maturen et al.    | 2013 | USA     | 77  | F      | L    | No       | Yes           | Embolization | N         | CT      | 18.0  | 3     | pos    | LR + M   | AWD       | 30        |
| 60   | Maturen et al.    | 2013 | USA     | 62  | F      | L    | No       | No            | Embolization | N         | CT      | 5.5   | 3     | neg    | *        | NED       | 46        |
| 61   | Maturen et al.    | 2013 | USA     | 43  | M      | L    | No       | No            | CT + XRT     | N         | No       | 5.0   | 3     | neg    | M        | AWD       | 36        |
| 62   | Maturen et al.    | 2013 | USA     | 69  | M      | R    | No       | No            | CT          | N         | No       | 6.1   | *     | *      | *        | NED       | 36        |
| 63   | Maturen et al.    | 2013 | USA     | 42  | M      | L    | No       | No            | No           | N         | CT      | 4.0   | 3     | *      | LR + M   | NED       | 26        |
| 64   | Saltzman et al.   | 2015 | USA     | 73  | F      | L    | No       | No            | No           | LAP N     | No       | 4.5   | 3     | neg    | *        | NED       | 6         |
| 65   | Chougule et al.   | 2015 | India   | 50  | F      | R    | No       | No            | No           | N         | No       | 6.4   | *     | neg    | *        | NED       | 15        |
| 66   | Devlin et al.     | 2015 | UK      | 68  | M      | R    | No       | No            | No           | LAP N     | No       | 3.0   | 2     | neg    | *        | NED       | 12        |
| 67   | Novak et al. (case report) | 2016 | Slovenia | 46  | F      | L    | No       | No            | No           | C         | XRT     | 12.0  | 3     | neg    | M        | AWD       | 24        |

RTNBL = retinoblastoma; WI = vascular wall invasion; N = nephrectomy; T = tumorectomy; C = compartment resection; LR = local recurrence; M = metastases; NED = no evidence of disease; AWD = alive with disease; DOD = died of disease; * = unknown. System used for tumor grading was not defined in the articles.